Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to announce Dr. Chris Bond has been promoted to Chief Scientific Officer.
VANCOUVER, British Columbia, March 28, 2023— Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to announce Dr. Chris Bond has been promoted to Chief Scientific Officer. With more than two decades’ experience in cell therapies, gene editing, and cell engineering—working with biotechnology and pharmaceutical companies, including Kite, Celgene, Juno Therapeutics, OncoMed, and Genentech—Dr. Bond joined Notch in January 2021. Over the past two years, in his role as Senior Vice President, Research and Early Development, he has led the team accelerating development of Notch’s iPSC-derived T cells.
Notch’s former Chief Scientific Officer, Dr. Peter Zandstra, will continue in a new role as Notch’s Senior Science and Technology Advisor. He will also co-chair Notch’s Scientific Advisory board alongside his Notch co-founder, Dr. Juan-Carlos Zúñiga-Pflücker, who has been named Notch’s Scientific Advisor Emeritus.
“This is a well-deserved promotion for Chris. He has led our recent advances generating highly functional T cells from our scalable iPSC platform, which we believe are best-in-class, positioning Notch as the leader in T cell development,” says David Main, President and Chief Executive Officer of Notch. “We are also grateful every day to Peter and Juan-Carlos for their tremendous contributions to Notch and look forward to their continued involvement as we keep working to maximize the benefits of cell therapies.”
About Notch Therapeutics
Notch is an early-stage biotechnology company working to maximize the benefit of cell therapies through a proprietary T cell-production platform that combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells. (www.notchtx.com.)
Media Contact:
Megan Helmer
Puzzlewood Communication Inc.
1.604.240.5223
mhelmer@notchtx.com